Press communication
Lund, Sweden, December 4 2023
This is a translation of the Swedish press release published 2023-12-04

Neola Medical AB (publ) has started a subsidiary in the USA as part of the upcoming launch of Neola® on the American market. The company’s American operations will be managed through Neola Medical, Inc., Delaware, and the office in Palo Alto, California, USA.

“The founding of Neola Medical, Inc. is an important step for our launch of Neola® in the U.S. as we believe that the formation of the company on American soil will play a major role for our positioning and growth in the market in the U.S. It opens up for cooperation with more American hospitals and key opinion leaders and simplifies the management of our business and daily activities from our office in Palo Alto, Silicon Valley, USA,” comments Hanna Sjöström, CEO Neola Medical.

For the time being, the daily operations of the subsidiary Neola Medical, Inc. are run by the team at the head office in Lund, together with American consultants. During the next two years, the team in Lund will be frequently on site in the U.S. for studies and to start up the daily operations. In the long term, Neola Medical will evaluate adding an American team that runs the operations on site in the U.S. with the support of key personnel at the head office in Lund.

Read the press release in Swedish here: Neola Medical AB startar dotterbolag i USA

For further information, contact:
Hanna Sjöström, CEO Neola Medical, phone: +46 (0)760-10 71 16, e-mail: hanna.sjostrom@neolamedical.com


Neola Medical AB (publ) develops medical technology device for continuous monitoring of preterm born infants’ lungs. Immediate detection of complications provides the possibility of early treatment and improved health care. The patented technology is based on a spectroscopic method developed at Lund University in Sweden. The company was founded in 2016 and is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more at www.neolamedical.com. The company’s Certified Adviser is FNCA Sweden AB.